Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Milton S. Hershey Medical Center
NRG Oncology
Hoffmann-La Roche
City of Hope Medical Center
Duke University
Five Prime Therapeutics, Inc.
Gilead Sciences
Stanford University
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
INSYS Therapeutics Inc